Disease relevance of DRG1

• The clinical evaluation of Drg1 in colorectal cancer has been limited [1].
• There was a trend for unilobar metastases with high Drg1 expression (P = 0.07) and a suggestion of improved 2-year survival (82.4% versus 69.6%, P = 0.148) [1].

High impact information on DRG1

• EXPERIMENTAL DESIGN: We examined Drg1 expression by immunohistochemistry in 131 patients with metastatic colorectal cancer enrolled in a clinical trial of adjuvant fluorouracil-based therapy from 1991 to 1995 [1].
• These findings suggest that DRG-1 may contribute to the dopamine-induced cell growth, which is negatively regulated by NADE [2].
• In flow cytometry cell cycle analysis, overexpression of DRG-1 in 293 or PC12 cells increased the population of cells in the S phase with a concomitant decrease in G0/G1 population [2].
• Furthermore, MTT assay showed that stable expression of DRG-1 in 293 cells could promote cell proliferation, and this promotion was suppressed by overexpression of NADE [2].
• Expression of human dopamine responsive gene-1 (DRG-1) is up-regulated in response to treatment of dopamine in the rat astrocytes [2].

Biological context of DRG1

• Assignment of developmentally regulated GTP-binding protein (DRG2) to human chromosome band 17p11.2 with somatic cell hybrids and localization to the Smith-Magenis syndrome critical interval [3].

Anatomical context of DRG1

• In the presented studies, DRG-1 was identified to be a conserved gene in the vertebrate and expressed abundantly in human testis, brain and skeletal muscle [2].

Analytical, diagnostic and therapeutic context of DRG1

• Assignment of the gene for a developmentally regulated GTP-binding protein (DRG2) to human chromosome bands 17p13-->p12 by in situ hybridization [4].

References